Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus

Liver Transplantation

Volumn 17, Issue 12, 2011, Pages 1380-1386

  Brandman, Danielle ^a   Pingitore, Andrea ^c   Lai, Jennifer C ^a   Roberts, John P ^a   Ferrell, Linda ^b   Bass, Nathan M ^a   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ALAMEDA COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; AGE DISTRIBUTION; ARTICLE; DISEASE SEVERITY; FATTY LIVER; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HYPERTENSION; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION;

BIOPSY; CHI-SQUARE DISTRIBUTION; FATTY LIVER; FEMALE; HEPATITIS C; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SAN FRANCISCO; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 82455205743     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22389     Document Type: Article

References (35)

1. Scientific Registry of Transplant Recipients. Accessed July 2011.
2. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P,. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77: 226-231. (Pubitemid 38155751)
3. Petta S, Cammà C, Di Marco V, Alessi N, Cabibi D, Caldarella R, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008; 103: 1136-1144. (Pubitemid 351677995)
4. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-423. (Pubitemid 351181308)
5. Foxton MR, Quaglia A, Muiesan P, Heneghan MA, Portmann B, Norris S, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006; 6: 1922-1999.
6. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9: 1406-1413.
7. AlDosary AA, Ramji AS, Elliott TG, Sirrs SM, Thompson DM, Erb SR, et al. Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl 2002; 8: 356-361. (Pubitemid 34467370)
8. Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA,. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004; 10: 349-355. (Pubitemid 38380307)
9. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G,. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364. (Pubitemid 32496971)
10. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al.; for HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
11. Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, et al.; for HALT-C Trial Group. Hepatology 2009; 49: 1828-1837.
12. Farrell GC, Larter CZ,. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43 (suppl 1): S99-S112.
13. Harrison SA, Torgerson S, Hayashi PH,. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-2047. (Pubitemid 37185803)
14. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P,. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121. (Pubitemid 41002048)
15. Batts KP, Ludwig J,. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-1417.
16. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.; for Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321. (Pubitemid 40770284)
17. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-790. (Pubitemid 43345017)
18. Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H Jr, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat 2008; 15: 129-136.
19. Vuppalanchi R, Chalasani N,. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317.
20. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109-1114. (Pubitemid 47305029)
21. Cua IH, Hui JM, Kench JG, George J,. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 723-731.
22. Cotler SJ, Kallwitz E, TenCate V, Bhushan A, Berkes J, Benedetti E, et al. Diabetes and hepatic oxidative damage are associated with hepatitis C progression after liver transplantation. Transplantation 2007; 84: 587-591. (Pubitemid 47429038)
23. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL,. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000; 6: 44-53. (Pubitemid 30123367)
24. Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 1287-1293.
25. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-1225. (Pubitemid 39425579)
26. Ridker PM, Buring JE, Cook NR, Rifai N,. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397.
27. Berg AH, Scherer PE,. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-949. (Pubitemid 40712793)
28. Matsuzawa Y,. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3: 35-42. (Pubitemid 43078211)
29. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J,. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54. (Pubitemid 38868922)
30. Zhu J, Wu J, Frizell E, Liu SL, Bashey R, Rubin R, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999; 117: 1198-1204. (Pubitemid 29512680)
31. Bridle KR, Popa C, Morgan ML, Sobbe AL, Clouston AD, Fletcher LM, Crawford DH,. Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl 2009; 15: 1315-1324.
32. Neff GW, Montalbano M, Slapak-Green G, Berney T, Bejarano PA, Joshi A, et al. A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection. Liver Transpl 2003; 9: 477-483. (Pubitemid 36621716)
33. Burra P, Loreno M, Russo FP, Germani G, Galligioni A, Senzolo M, et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl 2009; 15: 619-628.
34. Briceño J, Ciria R, Pleguezuelo M, de la Mata M, Muntané J, Naranjo A, et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009; 15: 37-48.
35. Lazzarini AL, Levine RA, Ploutz-Snyder RJ, Sanderson SO,. Advances in digital quantification technique enhance discrimination between mild and advanced liver fibrosis in chronic hepatitis C. Liver Int 2005; 25: 1142-1149. (Pubitemid 41782557)